Human papillomavirus L1 capsid protein (HPV L1) (types 6, 11, 16, 18, 31, 33, 45, 52, 58) (HPV L1 (6, 11, 16, 18, 31, 33, 45, 52, 58))

The Human Papillomavirus (HPV) L1 capsid protein is the primary structural component of the viral shell, responsible for mediating viral attachment and entry into host basal epithelial cells (UniProt P03101). These proteins possess the unique ability to self-assemble into non-infectious virus-like particles (VLPs) that mimic the native virus's outer structure, making them ideal targets for prophylactic vaccines (Schiller & Lowy, 2012). The specific types 16, 18, 31, 33, 45, 52, and 58 are classified as high-risk due to their strong association with cervical, anal, and oropharyngeal cancers, while types 6 and 11 are low-risk types responsible for most cases of genital warts (CDC, HPV Vaccination). Drugs targeting these proteins, such as the 9-valent HPV vaccine, function by inducing high titers of neutralizing antibodies that bind to the L1 protein and prevent the virus from infecting host cells (FDA, Gardasil 9 Label). This immune intervention effectively blocks the viral life cycle before the establishment of a persistent infection, thereby preventing the development of HPV-related malignancies and lesions. The L1 protein is highly conserved within types but varies significantly between types, necessitating the multi-valent approach seen in modern vaccines to provide broad protection (PubMed PMID: 23034354).

Other names

HPV L1 major capsid proteinL1 proteinHPV 6/11/16/18/31/33/45/52/58 L1Virus-like particle L1 proteinHuman papillomavirus L1 capsid proteins for types 6, 11, 16, 18, 31, 33, 45, 52, and 58

Prophylactic immunization via virus-like particles (VLPs) that induce the production of type-specific neutralizing antibodies; these antibodies bind to the L1 protein on the virion surface, sterically hindering viral attachment to host cell receptors and preventing entry into basal epithelial cells (Schiller & Lowy, 2012; FDA, Gardasil 9 Label).